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Resumo 
 
Atualmente e segundo a Organização Mundial de Saúde (OMS), o cancro da mama é um 
dos oito cancros com maior taxa de prevalência e de mortalidade no mundo. Entre as 
mulheres, este ultrapassa em larga escala todos os outros cancros, sendo considerado a 
patologia com maior taxa de  mortalidade e o cancro com o maior número de casos 
diagnosticados, com uma  estimativa anual de 1,67 milhões de novos casos registados no 
mundo.  
Este é o cancro com maior taxa de prevalência nas mulheres em todo o mundo e 
atualmente é o segundo cancro com maior prevalência em Portugal em ambos os sexos, 
sendo apenas ultrapassado pelo cancro da próstata e estando à frente do cancro do pulmão 
e o cancro do colón. 
No nosso país, cerca de 8000 novos casos de cancro da mama são diagnosticados todos 
os anos; em Portugal,  aproximadamente 1500 mortes anuais devem-se a este carcinoma 
como principal causa de morte.  
Este é portanto considerado um problema grave de Saúde Pública a nível global devido à 
sua elevada incidência, morbilidade, mortalidade e elevado custo do tratamento. 
Vários são os fatores preditivos que podem ser considerados fatores de risco para este 
tipo de cancro: a existência de um familiar com um grau de parentesco próximo a quem 
já tenha sido diagnosticado cancro da mama, a idade, a idade da menarca, uso de 
medicação de contraceção ou de tratamento hormonal ou idade do nascimento do 
primeiro filho, entre outros. 
Não só o conhecimento dos fatores preditivos do cancro mas também o conhecimento 
dos fatores prognósticos têm sido objeto de vários estudos e determinante para a 
realização do melhor diagnóstico, da escolha do tratamento, da perspetiva de 
sobrevivência e da resposta patológica completa.  
O conhecimento destes fatores têm sido alvo de estudo por médicos oncologistas e 
investigadores, bem como a escolha do tratamento. Hoje em dia, esta é uma área em 
constante crescimento não só devido à investigação mas também às variadíssimas opções 
de combinação de tratamento e fármacos que é possível. Uma das áreas mais investigadas 
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nos dias de hoje é o tratamento direcionado e específico para o tipo de cancro sendo os 
anticorpos monoclonais uma das abordagens mais procuradas e utilizadas.  
Há vários fatores de prognóstico relevantes para caracterizar o tipo e gravidade de tumor 
que estão dividos em três categorias. Na categoria um encontram-se os fatores que 
revelam elevado valor terapêutico e de diagnóstico como é o tipo e grau histológico do 
cancro e o estadiamento do tumor de acordo com o sistema TNM, entre outros. Na 
segunda categoria encontra-se o recetor 2 do fator de crescimento epidérmico humano 
(HER2) que é o factor de prognóstico mais importante do nosso estudo e que é um critério 
de inclusão para o mesmo. 
Aproximadamente 25% de todos os casos registados de cancro da mama apresentam uma 
sobre expressão do HER2. A amplificação ou sobre expressão, ou ambos, do HER2 
(também conhecido como ERBB2), um recetor transmembranar tirosina quinase, está 
presente em cerca 35% dos tumores localmente avançados e metastáticos e 40% dos 
cancros inflamatórios da mama e está associado a doença agressiva e mau prognóstico.  
Trastuzumab é um anticorpo monoclonal humanizado cujo mecanismo de ação consiste 
em ligar-se ao domínio extracelular do recetor HER2 inibindo a sua atividade, sendo o 
único aprovado na terapia adjuvante em pacientes com HER2 positivo. 
Na terapêutica neoadjuvante, quando associado à quimioterapia, o trastuzumab melhorou 
significativamente a resposta patológica completa e reduziu o risco de recidiva, 
progressão da doença e morte quando comparado à quimioterapia isolada.  
Gianni et al referem no ensaio clínico “Neoadjuvant herceptin” (NOAH) que, o 
trastuzumab obteve uma resposta significativamente positiva nas taxas de resposta 
patológica completa em doentes com neoplasia da mama HER-2 positiva. Outro estudo 
refere ainda que a inclusão do trastuzumab resulta num aumento da sobrevida, bem como 
da taxa de cura em esquemas adjuvantes de doença operável.  
Após vários estudos que demonstraram a grande mais valia do uso desta terapêutica em 
Neoadjuvância, outros estudos quiseram avaliar em qual dos regimes deve ser aplicada 
esta terapêutica: sequencial ou concomitante. 
No nosso estudo, avaliámos qual dos dois regimes é mais indicado para o tratamento do 
cancro da mama HER2+ através de parâmetros como a resposta patológica completa, taxa 
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de sobrevivência, taxa de recidiva. Estes parâmetros foram determinados para as regiões 
da mama e axila individualmente e para os dois em conjunto (mama+axila). 
Foram avaliadas 89 doentes em 4 Hospitais do país: Hospital Cuf Cascais, Hospital Cuf 
Descobertas, Hospital Vila Franca de Xira e Hospital Doutor Fernando da Fonseca. Das 
89 doentes avaliadas, apenas 53 doentes possuíam o critério de inclusão no estudo 
(carcinoma HER2 positivo). 
Num total de 53 doentes avaliadas neste estudo, 32 foram avaliadas no esquema 
sequencial e 21 foram avaliadas no esquema concomitante. No final, o esquema 
concomitante demonstrou ter um melhor resultado para resposta patológica completa 
mama+axila com significância estatística. No caso da resposta patológica completa para 
a mama e para a axila individualmente, devido ao reduzido número da amostra não foi 
possível obter resultados com significância estatística.  
Também os efeitos adversos da terapêutica são factores que na hora da escolha do 
tratamento têm peso na decisão.  
Como é amplamente conhecido no mundo da Oncologia, a cardiotoxicidade das 
antraciclinas e do trastuzumab é um problema que não se pode ignorar. Esta 
cardiotoxicidade está actualmente parametrizada e é agrupada em duas classes distintas: 
cardiotoxicidade reversível onde está inserido o anticorpo monoclonal Trastuzumab  e a 
cardiotoxicidade irreversível onde se encontram as antraciclinas como é o caso da 
doxorrubicina. 
Um dos fatores de risco mais determinante para este efeito adverso é a idade, o que muitas 
vezes pode ser um problema pois a maioria deste tipo de carcinomas surge normalmente 
numa idade mais avançada.  
No nosso estudo provámos que  existe a possibilidade de ocorrência de efeitos adversos, 
podendo no entanto ser controlados recorrendo a terapêutica apropriada para o efeito, 
nomeadamente inibidores da enzima de conversão da angiotensina.  
O presente estudo, embora com uma amostra populacional reduzida e com baixa 
significância estatística, tem como objetivo tentar projetar alguns resultados que seriam 
expectáveis para um estudo realizado dentro dos mesmos moldes mas com uma maior 
dimensão. 
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Abstract 
 
Currently, according to the World Health Organization (WHO), breast cancer is one of 
the eight cancers with the highest prevalence and mortality rates in the world. Among 
women, this large-scale surpasses all other cancers being considered the pathology with 
the highest mortality rate and the cancer with the largest number of diagnosed cases being 
the annual estimate of 1.67 million new cases registered in the world. 
Approximately 25% of all registered cases of breast cancer have an overexpression of 
human epidermal growth factor receptor 2 (HER2). HER2 (also known as ERBB2), a 
transmembrane receptor tyrosine kinase receptor, is present in about 35% of locally 
advanced and metastatic tumors and 40% of inflammatory breast cancers and is 
associated with aggressive disease and poor prognosis. Trastuzumab is a humanized 
monoclonal antibody whose mechanism of action is to bind to the extracellular domain 
of the HER2 receptor inhibiting its activity, being the only one approved in adjuvant 
therapy in patients with HER2-positive. 
In neoadjuvant therapy, when associated with chemotherapy, trastuzumab significantly 
improved the overall pathologic response and reduced the risk of relapse, disease 
progression and death when compared to chemotherapy alone. 
Gianni et al reported in the "Neoadjuvant Herceptin" (NOAH) trial that trastuzumab 
obtained a significantly positive response in rates of complete pathological response in 
patients with HER-2 positive breast cancer. Another study reports that the inclusion of 
trastuzumab results in increased survival as well as the rate of cure in adjuvant regimens 
of operable disease. 
Our primary objective was to compare which quimiotherapic regimen - concomitant vs 
sequential – is the most effective and secure for the treatment of HER-2 positive breast 
cancer. 
The present study, although with a reduced population sample and with low statistical 
significance, aims to try to project some results that would be expected for a study 
conducted in the same molds but with a larger dimension. 
Keywords: Neoadjuvant, Breast cancer, HER2-positive, Trastuzumab, Sequential therapy, 
Concomitant therapy.  
 VII 
 General Index 
Acknowledgments ......................................................................................................................... II 
Resumo......................................................................................................................................... III 
Abstract ........................................................................................................................................ VI 
General Index ............................................................................................................................. VII 
Índex of Figures ........................................................................................................................ VIII 
Índex of tables ........................................................................................................................... VIII 
Índex of graph ........................................................................................................................... VIII 
Abbreviations list ....................................................................................................................... IX 
I. Bibliographic revision ............................................................................................................ 1 
1. Risk Factors of Breast Cancer ........................................................................................ 3 
2. Prognostic Factors of breast cancer ............................................................................... 8 
3. TNM System .................................................................................................................. 9 
4. Histopathologic types of breast cancer ........................................................................ 11 
5. Breast Cancer type HER2-positive .............................................................................. 13 
5.1 EGFR family receptors .......................................................................................... 13 
5.2 Trastuzumab ............................................................................................................ 15 
5.3 Treatment ................................................................................................................ 15 
6. Cardiotoxicity caused by the use of anthracyclines and trastuzumab .......................... 17 
II. Material and Methods .......................................................................................................... 19 
1. Study goals ................................................................................................................... 19 
2. Study design and settings ............................................................................................. 19 
3. Population .................................................................................................................... 19 
4. Data analysis ................................................................................................................ 20 
5. Statistical analysis ........................................................................................................ 20 
6. Constitution of the sample ........................................................................................... 20 
III. Results .............................................................................................................................. 21 
IV. Discussion ........................................................................................................................ 25 
V. Conclusion ....................................................................................................................... 29 
VI. Bibliographic references .................................................................................................. 30 
VII. Annex ............................................................................................................................... 37 
1. Inclusion criterion (according to TNM system) ........................................................... 37 
2. Study variables and their definition ............................................................................. 38 
3. Variables of clinical staging ......................................................................................... 39 
4. New York heart association classification ................................................................... 40 
 VIII 
 
Índex of Figures 
Figure 1- Incidence rate of breast cancer (2) ................................................................................. 1 
Figure 2- Evolution of oncological diseases in Portugal. Adapted from National Cancer Program 
published by the DGS in 2015.(5) ................................................................................................. 2 
Figure 3- Examples of mamographic density (adapted from medscape) ....................................... 7 
Figure 4- Signalling pathways activated by her2. (33) ................................................................ 14 
 
 
 
Índex of tables 
Table 1- Risk Factors of breast cancer (7) ..................................................................................... 4 
Table 2- Prognostic factors in breast cancer(21) ........................................................................... 9 
Table 3- Treatment groups and median and maximum ages ....................................................... 21 
Table 4- Percentage of positive receptors in two different groups. ............................................. 22 
Table 5- Results of pathological complete response .................................................................... 22 
Table 6- Study variables and their definitions ............................................................................. 38 
Table 7- Number of patients with different variables os clinical staging .................................... 39 
Table 8- Degree of heart failure according to symptoms. Adapted from the New York Heart 
Association. .................................................................................................................................. 40 
 
 
 
Índex of graph 
Graph 1- TNM Staging criteria of breast cancer(21) ................................................................... 10 
Graph 2- Histopathologic types of the most common cancers of the breast(21) ......................... 12 
Graph 3- PCR results and their statistical significance according to the chi-square test. ............ 24 
 IX 
Abbreviations list 
 
AC- Adriamycin and Cyclophosphamide Therapy  
ACE inhibitor- Angiotensin-converting-enzyme Inhibitor 
ADCC- Antibody Dependent Cellular Citotoxicity 
AKT- Protein kinase B 
AT – Anthracyclines and Trastuzumab therapy 
Bcl-2- B-cell Lymphoma 2 
DFS- Disease Free Survival 
DGS- General Health Department of Portugal 
DNA – Deoxyribonucleic Acid 
EGFR- Epidermal Growth Factor Receptor 
EMA- European Medicine Agency 
ERBB2- Human Epidermal Growth Factor Receptor 2 
ER- Estrogen Receptor  
ERK- Extracellular signal–regulated Kinases 
HER 2- Human Epidermal Growth Factor Receptor 2 
HF- Heart Failure 
IHC- Immunohistochemistry 
LVEF- Left Ventricular Ejection Fraction 
MAH- Marketing Authorization Holder 
MEK- Mitogen-activated Protein Kinase  
Mib-1-Monoclonal Antibody of Cell Proliferation 
mTOR- Mechanistic Target of Rapamycin 
NYHA- New York Heart Association 
 X 
OS- Overall Survival 
p53- Tumor Gene Suppressor 
PCR- Pathological Complete Response 
PI3K- Phosphoinositide 3-kinase 
PR- Progesterone Receptor 
PS2- Estrogen Response Gene 
RAF- Rapid Accelerated Fibrosarcoma 
RAS- A family of genes that may cause cancer when they are mutated 
TH- Taxol (paclitaxel) and Herceptin (Trastuzumab) 
WHO- World Health Organization 
 1 
I. Bibliographic revision 
 
According to World Health Organization (WHO), breast cancer is one of the eight most 
common cancers worldwide in terms of incidence and cause of death,  910 000 new cases 
occur yearly  and the number of total deaths is around 360 000. (1) 
Breast cancer is the second most common cancer in the world and, by far, the most 
frequent cancer among women with an estimated 1.67 million new cancer cases 
diagnosed in 2012 (25% of all cancers). (2)  
At a global level, it is in the USA that there is the highest incidence rate of breast cancer, 
followed by Europe and Australia. (2) 
 
Figure 1- Incidence rate of breast cancer (2)  
 
Breast cancer is proved to be the second cause of death in the most developed countries 
where the first is lung cancer. On the contrary, in less developed countries it occupies the 
fifth place on the list of the most lethal cancers. (2) 
The combination of a high incidence and a favourable prognosis makes breast cancer the 
most prevalent tumour: in the last five years approximately 4.4 million surviving women 
have been diagnosed breast cancer around the world. (3)  
In Portugal it is  also  the most frequent tumour in women, with about 8000 new cases 
and 1500 deaths per year. (3) 
According to the National Cancer Program published by the DGS in 2015, breast cancer 
is the second cancer with the highest gross incidence rate per 100,000 population, being 
only surpassed by prostate cancer. When only female sex is referred, it goes far beyond 
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all other carcinomas, having an almost three times higher rate than the second most 
recorded.  
Regarding the progression of oncological diseases in Portugal, breast carcinoma also 
stands out among all the others because it is a pathology that since 2006 has been showing 
a growing progression, reaching the top of oncological diseases in 2010 in Portugal, 
overlapping  carcinomas such as prostate, colon, lung, stomach, etc. (4) 
The following graph shows the gradual growth of oncological diseases in Portugal from 
2006 to 2010: the breast carcinoma occupies the most prominent place. 
 
 
Figure 2- Evolution of oncological diseases in Portugal. Adapted from National Cancer Program published by the 
DGS in 2015.(5) 
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1. Risk Factors of Breast Cancer 
About one-half of newly diagnosed breast cancers can be explained by already known 
risk factors, such as age at menarche, first live birth, menopause, and proliferative breast 
disease. An additional 10 percent is associated with a positive family history. In addition, 
risk may be modified by demographic, lifestyle, and environmental factors, although their 
association with breast cancer has not been clearly demonstrated. (6)
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The established risk factors for breast cancer and the degree of risk associated with these 
factors as well as their relative risk are described in the following table: 
Table 1- Risk Factors of breast cancer (7) 
 Established risk factors of breast cancer 
Factors Low risk High risk Relative risk 
Mother or sister 
with breast cancer 
- + 2.6 
Age 30 to 34 70 to 74 18.0 
Age at menarche >14 <12 1.5 
Age at first birth <20 >30 1.9 to 3.5 
Age at menopause <45 >55 2.0 
Use of 
contraceptive pills 
Never Past/Current use 1.07 to 1.2 
Hormone 
Replacement 
Therapy (estrogen 
+ progesterone) 
Never Current 1.2 
Alcohol None 2 to 5 drinks/day 1.4 
Breast density 
mammography 
(%) 
0 ≥75 1.8 to 6.0 
Bone density Lowest quartile Highest quartile 2.7 to 3.5 
History of a 
benign breast 
biopsy 
No Yes 1.7 
History of atypical 
hyperplasia on 
biopsy 
No Yes 3.7 
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All factors described in the table above are correlated with a specific factor in common: 
the level of estrogen and progesterone. Several studies have recently provided clear 
evidence for the role of endogenous estrogen in the development of breast cancer. For 
example, a postmenopausal woman with relatively high estrogen concentrations had an 
approximately twofold risk of breast cancer compared with postmenopausal women with 
low serum concentrations. (8) 
Increasing age - the older you get the greater risk of breast cancer you have. From birth 
to the age of 49 the probability for a woman of developing breast cancer is of 1.9%. The  
previous percentage increases significantly with increasing age; the average increase is 
about 6.8% at the age  of 70 (1 in 15 women). (9) 
Menarche and menopause age - early menarche and late menopause maximize the 
number of ovulatory cycles during which a woman is exposed to high levels of estrogen 
and progesterone. A decrease of about 20% in breast cancer risk results from each year 
that menarche is delayed. Regular menstrual cycles from the first year of menstruation is 
an important factor for the decrease of risk of breast cancer. (8) 
Age at first birth - results of 47 epidemiologic studies show that the younger a woman 
gives birth to her firth child, the lower the risk of breast cancer. The younger the woman 
gives birth for the first time, the more relative risk declines: about 3% each year. It has 
been proposed that full cellular differentiation, which occurs in the gland during and after 
pregnancy, protects the breast from breast cancer development. First birth at a later age 
may confere a greater risk than nulliparity because of additional proliferative stimulation 
of breast cells that are more likely to be fully developed and perhaps more prone to cell 
damage. (8,10) 
Lifestyle factors - alcohol, tobacco and night shift work are three social conditions that 
significantly increase the risk of developing breast cancer.  
Compared to non-drinkers, daily consumption of one and two drinks was associated with 
a 10% and 21% increase in breast cancer risk, respectively. (11)  
Although the association between alcohol and breast cancer risk is already well known, 
its association with tobacco was still unclear until recent studies. In a recent 2015 study, 
strong associations were found between the risk of developing breast cancer and exposure 
to tobacco (at what age you start smoking, how long you’ve been smoking, number of 
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cigarettes you smoke per day, approximate number of cigarettes during the exposure 
time). (12) 
A study carried on nurses performing rotating shifts (day and night) concluded that 
working shifts after midnight is associated with an increased risk of breast cancer. The 
risk found was similar to that previously studied for female flight attendants on aircraft. 
(13) 
Dense breast tissue - in 1976, Wolfe described an association between a qualitative 
classification of mammographic densities and the risk of breast cancer. Breast density, a 
measure of the extent of radiodense fibroglandular tissue in the breast, has the potential 
to be used as a predictor of breast cancer risk, to monitor risk- lowering interventions and 
as an intermediate end point in studies of breast cancer etiology. A woman whose density 
is greater than 75%, has 4 to 5 times more probability of developing breast cancer 
compared to a woman with low or no breast tissue density. (14–16) 
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Figure 3- Examples of mamographic density (adapted from medscape) 
Legend: Panel A: 0% of density; Panel B: <10% density; Panel C: 10 to <25 % density; Panel D: 25 to <50% density; 
Panel E: 50 to <75% density; Panel F: >75% density. 
Bone density - bone mineral density is an excellent regulator of circulating estrogen 
levels. This is due to the high number of receptors of this hormone and its high selectivity 
to it. Women with a high bone mineral density have a higher risk of developing breast 
cancer. (17,18) 
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2. Prognostic Factors of breast cancer 
 
The natural history of breast cancer indicates that the clinical course of the disease and 
survival vary from patient to patient. This variation is determined by a complex series of 
factors, such as the difference in the speed of tumour duplication, the potential for 
metastatization of the tumour and sociodemographic aspects as well as  those related to 
the patient's immunological, hormonal and nutritional condition. These factors  influence, 
directly or indirectly, the disease survival rate and other related mechanisms. Prognostic 
factors are possible parameters to be measured at the time of diagnosis and serve as a 
predictor of patient survival. (19,20) 
The literature states an inverse relationship between tumour size and survival, whereas 
the presence of lymph nodes is associated with the disease recurrence in the first decade 
after treatment. High number of affected lymph nodes and involvement of the axillary 
apex and internal mammary lymph nodes indicate worse prognosis. (20) 
Some prognostic factors have a dual function: besides playing their role as a prognostic 
factor, they also play a very important role as a predictive factor, thus allowing the 
establishment of specific therapies for the treatment of the tumour. (19)  
According to College of American Pathologists Consensus Statement in 1999, the 
prognostic factors in Breast Cancer were stratified in three categories:  
-Category one: includes factors proven to be of prognostic import and useful in clinical 
patient management. (21)  
- Category two: includes factors that had been extensively studied biologically and 
clinically, but whose import remains to be validated in statistically robust studies. (21) 
-Category three: includes all the other facts that haven’t been sufficiently studied so far 
to demonstrate their prognostic value. (21) 
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Those prognostic factors are included in the following table: 
Table 2- Prognostic factors in breast cancer (21) 
Category 1 Category 2 Category 3 
• TNM Stage 
• Sentinel 
Lymphadenectomy 
• Histological Grade 
• Histological Type 
• Hormone Receptor 
Status 
• Mitotic Figure Count 
• HER2 
• p53 
• MIB-1 
• DNA Analysis: Phase 
Fraction 
• DNA Ploidy Analysis 
• Tumour Angiogenesis 
• Epidermal Growth 
Factor Receptor 
• Transforming Growth 
Factor-α 
• bcl-2 
• pS2 
• Cathepsin D 
 
Numerous studies carried out in many countries, have shown the value of using tumour 
size and nodal status to estimate prognosis in breast cancer. It is also widely accepted that 
age, race, histologic type, hormonal receptor status, and several other significant variables 
may influence an individual's prognosis. (22) 
 
3. TNM System 
 
The International Union Against Breast Cancer (UICC) proposed in 1954 breast cancer 
to  be classified according the TNM system. This system characterizes the tumour 
according to alphanumeric codes and it is used in several malignant carcinomas according 
to the following codification: (21,23) 
• T - describes the size of the main tumour and invades the surrounding tissue. 
• N - describes whether there is involvement of lymph nodes near the main tumour. 
• M - describes distant metastasis. 
This classification is also divided into stages: 0, I, IIA / IIB, IIIA, IIIB, IIIC and IV. The 
following table describes the characteristics of each staging. 
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Graph 1- TNM Staging criteria of breast cancer (21) 
 
Stage 0
•T1 (≤2cm)
•T1mic (microinvasion≤0,1cm)
•T1a (0,1cm<T≤0.5cm)
•T1b (0,5<T≤1cm)
•T1c (1cm<T≤2cm)
•N0 (no regional lymph nodes)
•M0 (no metastasis)
Stage I
•T2 (2cm<T≤5cm)
•N1 (metastasis to movable ipsilateral axillary lymph nodes)
•pN1 (metastasis in 1-3 axillary lymph nodes)
Stage 
IIA/IIB
•T3 (>5cm)
•N2a (metastasis in ipsilateral axillary lymph nodes)
•pN2 (metastasis in 4-9 axillary lymph nodes)
Stage IIIA
•T4 (any size with direct extension to chest wall or skin or both and inflammatory)
•N2 (metastasis in ipsilateral axillary lymph nodes fixed or matted)
•pN2 (metastasis in 4-9 axillary lymph nodes)
•pN2b (metastasis in clinically apparent internal mammary lymph nodes in the
absence of axillary lymph node metastasis)
Stage IIIB
•Any T
•N3 (metastasis in ipsilateral infraclavicular lymph nodes involvement, or in
ipsilateral internal mammary lymph nodes and in the presence of clinically evident
axillary lymph node metastasis or metastasis in ipsilateral infraclavicular lymph
node with or without axillary or internal mammary lymph nodes involvement)
•N3a (infraclavicular)
•N3b (axillary or internal mammary)
•N3c (supraclavicular)
•pN3 (metastasis in ≥10 axillary nodes)
Stage IIIC
•Any T
•N3
•M0
Stage IV
•Any T
•Any N
•M1
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4. Histopathologic types of breast cancer 
 
In addition to the stage classification of breast cancer, it is also classified by their 
histological type. There are several morphological patterns and these are important not 
only to define their severity but also to predict the prognosis and evolution of carcinoma. 
(24,25) 
Most breast tumours generally occur in the ducts or lobes, and are then referred to as 
ductal carcinomas or lobular carcinomas. Regarding the prognosis of breast cancer, those 
with the worst prognosis are invasive ductal carcinoma and inflammatory carcinoma, 
although the later has a very low prevalence compared to other histological types. (26,27) 
The following chart describes the various types of breast cancer classified according to 
their histological grade. 
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Graph 2- Histopathologic types of the most common cancers of the breast (21) 
 
 
 
Carcinoma
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5. Breast Cancer type HER2-positive 
 
5.1 EGFR family receptors 
 
Approximately 20% to 25% of invasive primary breast cancers overexpress or have an 
HER2 amplification. (28)   
The human epidermal growth factor receptor 2 oncogene, better known as HER2 +, 
belongs to the human epidermal growth factor (EGFR) family of 4 different types of 
tyrosine receptors (HER 1, HER 2, HER 3, HER 4). (29) 
Each of these receptors consists of an extracellular domain where binding to the 
respective ligands occurs, a transmembrane domain and a cytoplasmic domain where 
intracellular signalling and development processes are activated. (30) 
Although it is not yet known which HER2 receptor ligand is responsible for triggering 
the whole process, it is known that it has intracellular tyrosine kinase activity and plays a 
key role in the activation of intracellular signalling pathways that control cell growth and 
differentiation of the epithelial cells and vascularization around them (angiogenesis). 
(31,32) 
After binding of ligand to the respective receptor, a sequence of conformational 
rearrangements with the formation of homodimers and heterodimers between the 
different receptors of the EGFR family is promoted. After this conformational 
rearrangement, the receptor is internalized, followed by phosphorylation and activating 
signalling such as the PI3K/AKT/mTOR pathway and the RAS/RAF/MEK/ERK 
pathway. (30) 
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The mechanism described above is demonstrated in the following figure: 
 
Figure 4- Signalling pathways activated by her2 (33) 
 
Impaired ERBB2 signalling is associated with the development of neurodegenerative 
diseases, such as Multiple Sclerosis and Alzheimer disease, whereas excessive ERBB2 
signalling is associated with the development of cancers. (34) 
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5.2 Trastuzumab 
 
Trastuzumab (whose trade name developed by Roche® is Herceptin®) is a humanized, 
monoclonal antibody derived from recombinant Deoxyribonucleic acid (DNA) and 
specifically designed to bind with high affinity to the Human Epidermal Growth Factor 
Receptor 2. Trastuzumab binds to ERBB2 receptor in the juxtamembrane portion of the 
extracellular domain. This binding prevents the receptor from activating its intrinsic 
tyrosine kinase, which in turn prevents the activation of several signaling pathways 
leading to cell proliferation. (34) 
There are some mechanisms proposed for the functioning of this type of specific antibody. 
One of the accepted mechanisms involves the prevention of HER2-HER3 heterodimer 
formation, one of the most active heterodimers, and thought to have the ability to activate 
the signalling cascade in the absence of its true ligand. (35) 
The other mechanism (antibody-dependent cellular cytotoxicity ADCC) is related to a 
cell-mediated autoimmune defence mechanism in which an effector cell of the immune 
system actively lyses a target cell whose membrane surface is covered by specific 
antibodies. Trastuzumab may also play an active role in the process of internalization and 
degradation of the HER2 receptor as well as the cleavage and release of the receptor into 
the extracellular domain. (34) 
 
 
5.3 Treatment  
 
The use of Trastuzumab was approved by the European Medicines Agency in August 
2000 with the following indication: “Herceptin is indicated for the treatment of patients 
with metastatic breast cancer whose tumours overexpress HER2: as monotherapy for the 
treatment of those patients who have received at least two chemotherapy regimens for 
their metastatic disease. Prior chemotherapy must have included at least an anthracycline 
and a taxane unless patients are unsuitable for these treatments. Hormone receptor 
positive patients must also have failed hormonal therapy, unless patients are unsuitable 
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for these treatments.” In 2010, Trastuzumab (Herceptin®, Roche®) has been approved 
for use in the treatment of HER2-positive gastric cancer by the European Commission. 
(36,37)  
Trastuzumab was initially approved to be used in the adjuvant treatment of early-stage 
HER2-positive breast cancer. Adjuvant therapies are used as a primary treatment 
(surgery), whose main goal is to increase the long-term hypothesis of disease-free 
survival. An example of a chemotherapy regimen is "AC + TH", which stands for 
Doxorubicin and Cyclophosphamide followed by Paclitaxel and Trastuzumab. (34,38) 
Recently, HER2-targeted therapy has been approved by EMA to be used in the 
neoadjuvant setting. This appeal was proposed by Marketing Authorization Holder 
(MAH) and supported by the pivotal study "NOAH" which demonstrated the efficiency 
of Trastuzumab treatment in combination with neoadjuvant chemotherapy for locally 
advanced (including inflammatory) disease or tumours> 2 cm in diameter. (36,39) 
 Neoadjuvant therapy has an important role in patients with locally advanced and 
inflammatory cancers and consists of the application of pharmacological therapy prior to 
initiating primary therapy (surgery) with the aim of treating distant micrometastases, 
downstaging tumours, improving operability and to increase the chance of long-term 
survival disease-free period. Moreover, it facilitates breast-conserving surgery by 
downstaging the primary tumour and axillary nodes. Besides that, the pathologic response 
to neoadjuvant chemotherapy provides valuable prognostic information. (34,39) 
As for the concomitant therapy (AT), it was conducted according to the NOAH protocol 
with IV administration and proceeded as follows: 
• Doxorubicin 60 mg/m2 + Paclitaxel 150 mg/m2 + Trastuzumab (8 mg/kg on 1st 
administration, 6 mg/kg in subsequent administrations for 3 cycles of 21 days) 
• Then paclitaxel 175 mg/m2 + Trastuzumab 6mg/kg (trissemanally for 4 cycles) 
• Finally, Cyclophosphamide 600 mg/m2 + Methotrexate 40 mg/m2 + Fluorouracil 
600 mg m2 (on days 1 and 8 of each cycle) + Trastuzumab 6 mg/kg (on day 1 of 
each cycle for 3 cycles of 4 weeks ) 
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By contrast, the sequential therapy treatment group followed the treatment protocol 
983121 as follows: 
• AC + PT: Doxorubicin 60mg / m2 + Cyclophosphamide 600mg / m2 every 
3 weeks for 4 cycles. 
• Followed by Paclitaxel 80 mg / m2 (12 administrations weekly) + 
Trastuzumab at the standard dose every 3 weeks. 
In both groups, treatment with Trastuzumab was completed twelve months after the 
surgical procedure, except for cases of disease progression. 
 
 
6.  Cardiotoxicity caused by the use of anthracyclines and 
Trastuzumab 
 
The cardiotoxicity caused by anthracyclines used in oncological treatments is considered 
to be one of the most serious adverse effects leading to a higher morbimortality rate, 
which may occur acutely after the end of treatment or up to two weeks later. If it only 
manifests up to two years after the end of treatment, it will turn chronic. (40,41) In order 
to diagnose the presence of cardiotoxicity it is necessary to comply with one of the 
following parameters: 
• Presence of cardiomyopathy with reduced Left Ventricular Ejection Fraction 
(LVEF) with global compromise or with more evident segmental alterations in 
the septal region; 
• Symptoms associated with cardiac failure; 
• Tachycardia detection; 
• Reduction of LVEF by at least 5% for levels of less than 55% with signs or 
symptoms of heart failure, or a decrease in LVEF of at least 10% for levels of less 
than 55% in the absence of signs or symptoms compared to Values of the 
individual. (42,43) 
There are several adverse effects that may occur due to the use of these drugs, including 
arterial hypertension, thromboembolic disease, pericardial diseases, arrhythmias and 
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myocardial ischemia. Heart failure with ventricular systolic dysfunction is highlighted as 
the most serious adverse effect. (40,41) 
It was already known that the use of anthracyclines as an anti-neoplastic agent had the 
adverse effect of cardiomyopathy, which was irreversible, when cumulative doses of this 
drug were used. As time went on, it has also been found that Trastuzumab also causes 
cardiomyopathy. However, it is not dose-dependent and is not an irreversible effect, and 
the situation may reverse with the end of treatment. (40,41) 
Two groups of agents causing cardiotoxicity are then classified: group I where 
anthracyclines such as Doxorubicin and Cyclophosphamide are inserted, which cause 
irreversible myocyte lesion and are dose-dependent; and group II where Trastuzumab and 
Sunitinib are inserted which cause reversible transient dysfunction in myocytes and are 
not dependent on the dose used in the treatment. (40,41)  
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II. Material and Methods 
 
1. Study goals 
Our primary objective was to compare which quimiotherapic regimen - concomitant vs 
sequential – is the most effective and secure for the treatment of HER-2 positive breast 
cancer. 
The effectiveness was assessed by the complete pathological response which is strongly 
associated with favourable long-term survival rates. (44) 
The degree of cardiotoxicity was also evaluated – as a benchmark of treatment security 
- due to the side effect of using both anthracyclines and Trastuzumab. 
 
2. Study design and settings 
This is a retrospective cohort study based on the clinical processes of a selected 
population of 89 breast cancer patients, diagnosed and followed between 2008 and 2016. 
The patients referred to above, were diagnosed and followed up at the Oncology services 
of four Portuguese hospitals: CUF Cascais Hospital, CUF Descobertas Hospital, Vila 
Franca de Xira Hospital and, Prof. Doutor Fernando da Fonseca Hospital. 
This study was conducted with the approval of institutional ethics committee. No 
informed consent was obtained with each individual patient because it was a retrospective 
patient chart review-base study. 
 
3. Population 
Among the 89 patients selected with breast cancer, the inclusion criterion was applied to 
define the final sample: indication of the Multidisciplinary team (MDT) for Neoadjuvant 
chemotherapy. The criteria defining the indication for neoadjuvant chemotherapy are 
described in annex 1. 
53 patients (59,6%) selected out of 89 patients,  fulfilled the inclusion criteria in the study 
and from these, two treatment groups were formed: the first group, consisting of 32 
patients, was treated in a sequential neoadjuvant therapeutic scheme with Anthracyclines 
and Trastuzumab (A-T) and the second group, consisting of 21 patients, was treated in a 
concomitant neoadjuvant therapeutic scheme with Anthracyclines and Trastuzumab 
(AT). 
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4. Data analysis 
The study database consists of 35 clinicopathological variables that are described and 
defined in annex 2. 
 
5. Statistical analysis 
Data were analysed using SPSS software version 23.0. The comparisons between the 
categorical variables were performed using the chi-square test. The value of statistical 
significance considered was p <0.05. 
 
6. Constitution of the sample 
From the initial population of 89 patients with breast carcinoma, 53 patients were 
included in the study because they demonstrated the inclusion criteria. Thus, the final 
sample consists of 53 patients whose average age is of 52.11 years. The diagnosis and 
treatment of the disease occurred between 2008 and 2016. 
 
,
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III. Results 
 
The sample population selected according to inclusion criteria (53 patients) at an average 
age of 52.11 years, a median of 52 and the respective standard deviation of 12.48 years, 
was separated into the two distinct treatment groups (AT vs A-T). In the following table, 
the dimensions of the groups are specified, as well as the median age and the maximum 
age of each: 
Table 3- Treatment groups and median and maximum ages 
Treatment group AT A-T 
Median Age 55 50 
Maximum Age 69 83 
 
In the sequential treatment group, an 83-year-old patient was exceptionally included in 
the study, a too advanced age to be approved for Neoadjuvant therapy due to the 
complications of the cardiovascular disease that this therapy involves. This patient was 
accepted because of the favourable characteristics she presented: a T3N1 carcinoma 
(tumour with 10cm), an excellent performance status, no comorbidities at all and a very 
present family that was favourable family condition for the accomplishment of this type 
of treatment. 
Regarding the variables of clinical staging, these are described in annex 3 but it is 
important to point out some important aspects such as: 
• Forty-one percent of patients had a staging tumour IIIA (T4), but this was more 
prevalent in the concomitant treatment group (21 patients) than in the sequential 
treatment group (13 patients). In the sequential treatment group, there was a 
greater predominance of stage 2 tumours (tumour of diameter between 2 and 5 
cm). 
• Ninety-one percent of patients had no metastasis of the tumour at a distance; 
however, eighty-four percent of the patients had lymph nodes near the main 
tumour. 
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• In the total sample, there were 8 patients who did not have lymphatic nodules (N0) 
and were divided equally between the two groups (4 patients were in the AT group 
and the other 4 patients were in the A-T group). 
• Only 2 patients had distant metastasis and both were treated in the concomitant 
treatment group. 
For estrogen and progesterone receptors, an immunohistochemical analysis was 
performed on a section of tissue removed from the biopsy and an anti-ER and anti-PgR 
mouse monoclonal antibody was used. Patients had the most positive levels for these 
receptors, as might be expected. In the following table, the percentages concerning to the 
positive values for the two receivers are: 
Table 4- Percentage of positive receptors in two different groups. 
 AT A-T 
Estrogen receptor 71,4% 53,1% 
Progesterone receptor 52,4% 56,3% 
 
3 different situations were evaluated concerning the pathological complete response 
(PCR): breast, axilla, breast + axilla. In general, better results were obtained in the case 
of concomitant therapy: greater percentage of positive pathological complete response as 
well as a lower percentage of absence of pathological complete response. The results 
obtained are shown in the following table: 
Table 5- Results of pathological complete response 
Pathological Complete 
response 
AT A-T P 
Breast 
Positive 56,50% 43,5% 
0,055% 
Absent 0% 9,38% 
Axilla 
Positive 47,1% 52,9% 
0,31% 
Absent 4,76% 15,625% 
Breast + 
axilla 
Positive 60,9% 39,1% 
0,013% 
Absent 0% 9,38% 
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As for drug-induced cardiotoxicity, notably anthracyclines and Trastuzumab, out of the 
53 patients included in the study only 4 showed symptoms of cardiotoxicity and all  these 
patients belong to the concomitant treatment group. In the sequential treatment group, 
there were no reports about the presence of cardiotoxicity, except for 1 missing case that 
did not respond to the study. 
Regarding the disease progression parameter, we obtained similar values in the two 
treatment groups. In each group, 3 cases were reported, and a total of 6 women did not 
continue the 12-month treatment with Trastuzumab after the surgical procedure as they 
presented disease progression at the end of the treatment protocols. 
At the end of the study three deaths were counted, all of which from the concomitant 
treatment group, being these deaths related to the progression of the disease. 
Concerning the possible cardiac toxicity developed by the drugs used in the treatment 
(anthracyclines and Trastuzumab), an evaluation of the patient’s cardiac function was 
made at the beginning of the study. The LVEF calculated at the beginning of the 
treatments had a minimum of 53% and a maximum of 75% with a median of around 62% 
of ventricular ejection fraction. During treatment, four patients were signalled as having 
a worsening degree of cardiac dysfunction, all belonging to the concomitant treatment 
group.  
Two patients were recorded with a fall value greater than 10% of the LVEF (parameter 
necessary to diagnose cardiomyopathy), apparently without symptoms during treatment 
with adjuvant isolated Trastuzumab. Both patients stopped the treatment with 
Trastuzumab alone and an antihypertensive drug (ACE inhibitor) was introduced to try 
to reverse Trastuzumab-induced cardiomyopathy. This procedure was successfully 
completed and cardiomyopathy was reversed. Trastuzumab was successfully introduced 
again and the treatment was completed to the end with no further occurrence. 
The other two patients had treatment-associated symptoms of heart failure that were 
included in the Class II New York Heart Association classification. (NYHA classification 
is listed in annex 4). 
One of the patients developed heart failure even during the period of chemotherapy 
(Cyclophosphamide + Methotrexate + Fluorouracil + Trastuzumab). This patient 
suspended Trastuzumab for 8 months and after surgery and cardiac function 
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normalization resumed the treatment and was able to complete the 17 cycles of 
Trastuzumab foreseen in the treatment. The second patient developed heart failure already 
in the treatment period with Trastuzumab alone, having discontinued treatment and 
initiated appropriate medication for regression of symptoms. With improvement of the 
clinical picture, the treatment with the monoclonal antibody was started again. 
Regarding the statistical results and their meaning, they were analysed according to the 
chi-square test. Due to the short number of cases reported, it was not possible to use the 
chi-square test in the following analysis parameters: status, presence of cardiotoxicity, 
disease progression. The results obtained and their statistical significance are described 
in the following graph: 
Graph 3- PCR results and their statistical significance according to the chi-square test 
 
PCR breast
The chi-square test for this parameter 
showed a value of  (1) = 3.687 and p> 0.05, 
so that there was no statistical significance.
PCR axilla
The chi-square test for this parameter 
showed a value of  (1) = 1.021 and p> 
0.05, so that there was no statistical 
significance.
PCR 
breast+axilla
The chi-square test for this parameter 
showed a value of  (1) = 6.226 and p <0.05, 
where statistical significance was obtained 
with benefit to the concomitant scheme.
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IV. Discussion 
 
The results obtained confirmed the advantages previously demonstrated by other studies, 
especially in the field of neoadjuvant treatment. NOAH, a phase 3 international study in 
women with HER2-positive breast cancer, found that using Trastuzumab in the 
neoadjuvant setting almost doubled the rate of complete pathologic response and reduced 
the risk of relapse, disease progression and even death. (45) 
According to a study aimed at HER2 receptors, approximately 22% of early breast 
cancers, 35% of advanced and metastatic local tumours, and 40% of breast inflammatory 
tumours have this amplified receptor, which is a correlated with disease aggressiveness 
and poor prognosis . This receptor is also overexpressed in a gastric and gastroesophageal 
cancer subtype, whose prevalence is approximately 18%, in lung cancer approximately 
2% and in colon cancer approximately 1% . For this type of gastric cancer the use of this 
monoclonal antibody Trastuzumab is also approved and these are the only two indications 
approved by EMA. (46,47) 
In the ToGA Trial, it was demonstrated the added value in the use of HER2 receptor 
targeted therapy in gastric and gastroesophageal tumours with a statistically significant 
increase in the overall survival rate (OS). (48)  
The way the two types of cancer are diagnosed are different : while in breast cancer, the 
distribution of the antibody in the neoplastic cell is mostly circumferential, in the gastric 
one the distribution is generally incomplete and "U" or unilateral. Thus, the circularity of 
IHC staining is not a criterion for HER2 IHC in gastric cancer. Also in gastric cancer, 
there is an irregular pattern in the cells presenting areas with different HER2 scores which 
can lead to sampling errors when the biopsies are examined. In breast cancer, the pattern 
is usually regular and quite visible. (49,50) 
Although there are significant differences between the histology of the cells and 
consequently the way the HER2 receptor is expressed, it is interesting to make the 
comparison between breast cancer and gastric / gastroesophageal cancer by both aligning 
therapeutics and obtaining good results with the same type of therapeutic target.  
However, the adjuvant trial that tested Trastuzumab in HER2-positive gastric cancer was 
negative. And also the trial that tested double blockade with Pertuzumab + Trastuzumab 
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in metastatic HER2-positive gastric cancer was also negative. Therefore, HER2 blockade 
in gastric cancer has been much less efficacious than in breast cancer. 
The use if anti HER2 therapy in breast cancer with Trastuzumab has been revolutionary, 
however we still lack knowledge about the combination with Trastuzumab and 
anthracyclines because of cardiotoxicity concerns. The Neoadjuvant setting is the best 
experimental setup for answering this question which is what we did with this study. 
Neoadjuvant treatment has been the treatment of choice for patients with locally advanced 
breast cancer and is also generally advised in women with operable breast cancer because 
it is a treatment that enables breast preservation during surgery. This is a very 
advantageous factor for those who choose this type of treatment and it is possible due to 
previous chemotherapy treatments whose purpose is to minimize the lesion size. 
Besides that, there is also the choice between a sequential or a concomitant treatment 
regimens that depends on several factors such as tumour type, adverse effects or cardiac 
condition of the patient. 
Fornier et al. carried out a phase 2 study whose objective was to assess the responsiveness 
to treatment and adverse effects of 42 patients divided into 2 arms (sequential and 
concomitant). 42% of the patients of the concomitant treatment developed grade 3 
anaemia and 63% required  blood transfusion, while in the sequential arm, 23% developed 
grade 3 anaemia and 36% required blood transfusion. (51) 
The certainties are still few as to the type of sequence to be used in the treatment. 
Although the results of PCR, overall survival rates and disease free survival (DFS) are 
similar or inconclusive when choosing one or the other, it is known that concomitant 
treatment entails more adverse effects than sequential treatment. One of the advantages 
of sequential treatment is that each drug can be administered at its maximum tolerated 
dose avoiding adverse effects. (52)  
As shown in our study, although its statistical significance is poor since it is based on a 
very limited  sample size, concomitant treatment demonstrated better PCR in breast and 
breast + axilla analysis compared to sequential treatment, which only proved to be more 
favourable in the axilla. Also in this study, four patients showed a worsening degree of 
cardiac dysfunction, all belonging to the concomitant treatment group. Although small 
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and with little statistical significance, our study is a good mirror of what happens in large-
scale studies with this type of treatment. 
A phase 3 study conducted by Spanish Breast Cancer Research Group aimed at comparing 
sequential and concomitant therapy using the same drugs (Doxorubicin and Docetaxel) 
and assessing toxicity and response rates to treatment (PCR, OS, time to disease 
progression).  
The concomitant treatment group developed a high febrile neutropenia compared to the 
sequential group (29.3% versus 47.8%, respectively). Although the study was not 
powerful enough to clearly demonstrate which treatment regimen is the most 
advantageous, it was useful in assessing which one triggers more toxicity. (53) 
Cardiotoxicity is one of the most significant adverse effects of cancer treatment, and is 
responsible for considerable morbility and mortality. 
Several studies have shown that the only independent risk factors for cardiac events are: 
age (60 years or older) and low baseline LVEF (50-55%). (54) 
Recently, the American Society of Clinical Oncology has published guidelines for the 
prevention and monitoring of cardiac function in adult post-cancer treatment patients. 
This guideline suggests three criteria for inclusion of high-risk patients, and the patients 
treated in our study are included in the following criteria: treatment with low doses of 
anthracyclines (eg. Doxorubicin <250mg / m2) followed by Trastuzumab. (55) 
According to these guideline suggestions and also to the American College of Cardiology 
/ American Heart Association, heart failure is defined in four stages (A, B, C, D). Patients 
in stage A are eligible for primary prevention of heart failure which includes all patients 
who are receiving cardiotoxic therapy such as anthracyclines and Trastuzumab as it 
happens in our study. 
In our sample the four patients who developed cardiotoxicity were in the concomitant 
treatment group.  
Two of them had an asymptomatic LVEF reduction greater than 10% which was reversed 
with cardio protective therapy (ACEI). Moreover this adverse effect occurred in the 
adjuvant phase of treatment when patients were receiving only Trastuzumab but they had 
already received concomitant anthracyclines + Trastuzumab in the neoadjuvant setting.  
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The other two had symptomatic heart failure class II of NYHA: in one of them 
cardiotoxicity developed in the neoadjuvant phase of treatment while the other had that 
adverse effect during the adjuvant period. However, in both cases it was reversed with 
appropriate ACEI therapy. 
Our results are comparable with those found by Gianni et al. in the NOAH trial. In both 
studies patients who developed LVEF reduction were in the Trastuzumab group. 
Moreover in both samples most reduction was grade 1 in severity and reversible with 
targeted treatment. (39) 
In another study conducted with a sample of 95 patients diagnosed with anthracycline-
treated breast cancer followed by Trastuzumab, 19 patients developed cardiotoxicity 
within eight months of initiating anthracycline treatment. 13 of these 19 patients had total 
or partial reversibility approximately seven months after diagnosis date. (56) 
In general, Trastuzumab-induced cardiotoxicity is reversible with time and ACEI 
appropriate treatment. However, we cite two studies one from our group of a case of 
sudden death by arrhythmia and another of a nearly 40% down in LVEF which never 
returned to baseline even after stopping Trastuzumab. (57,58) 
In relation to the therapy used to control heart failure due to cardiotoxicity caused by 
oncological agents (stage A), the guidelines of the American College of Cardiology 
Foundation / American Heart Association Task Force suggest that we should use ACEI 
or ARB therapy. (59) 
As indicated in international standards, the heart failure control reported in our study was 
also done with ACEI. The main objective of this medication was to control or reverse the 
decrease in LVEF after diagnosis with or without associated symptoms. 
However, recent studies have suggested that there is a great advantage in using ACEI / -
blockers in prophylaxis to control the cardiotoxicity induced in particular by Trastuzumab 
and anthracyclines. In Wittayanukorn et al. study, the group of patients who emphasized 
prophylactic prevention of heart failure had a 21% risk reduction compared to those who 
did not. (60) 
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V. Conclusion 
 
At the end of this study, to our knowledge, this is one of the major studies trying to 
compare the concomitant and sequential therapy used in HER2-positive breast cancer. 
The comparison of these two therapies involves not only the study of the therapeutic 
pathological complete response but also demonstrates that other factors are decisive for 
the choice of neoadjuvant chemotherapy regimen such as short and long term toxicity. 
Our study showed that concomitant therapy was associated with increased PCR, and the 
one that obtained the best response to therapeutics. However, it has also been shown that 
it can lead to greater problems of cardiotoxicity and the possibility of heart failure, since 
out four patients with LVEF decrease were all in the concomitant arm. 
One way of assessing heart failure determination is the low LVEF. However, several 
studies have demonstrated that the determination of biochemical parameters like troponin 
are good indicators for this type of heart failure risk assessment. These factors should not 
be ignored and could be a new form of diagnostic method, proving to be a more reliable 
and more sensitive method than LVEF. (54) 
Also the way of using heart failure prevention medication is still uncertain. Although our 
study reveals that the use of ACEI after diagnosis of LVEF decrease is useful and 
reversible after stopping Trastuzumab for a few weeks, several studies have shown that 
there is a greater value in performing this therapy prophylactically. (60) 
The present study, although with a reduced sample size and with low statistical 
significance, aims to try to project some results that would be expected for a study 
conducted in the same setting but with large sample size. 
In addition, other steps must be taken to understand the benefit of choosing to use 
concomitant therapy with anthracyclines and Trastuzumab once it seems to be associated 
with increased PCR but also increased cardiotoxicity. This could be achieved, for 
example, with a broader follow-up of patients in order to understand which therapy 
achieves the disease free survival and overall survival.
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VII. Annex 
 
1. Inclusion criterion (according to TNM system) 
• T3 (>5 cm) + N0 
• T2  (2-5 cm) + N0 
• N+ (with any T) 
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2. Study variables and their definition 
Table 6- Study variables and their definitions 
Variables  
Hospital code  
Institutional identification number 
Gender 
Birthdate 
Age at diagnosis 
Date of diagnosis 
Peri-partum breast carcinoma Carcinoma develops between the last month 
of pregnancy and up to five months after 
delivery 
Histological classification Affected tissue type. (Described in I-5) 
Disease progression When the disease develops and invasion of 
other organs or tissues that were previously 
unaffected 
Date of disease progression  
Date of the last follow-up 
Status Life/Death 
ER (Estrogen receptors) Proteins that bind to estrogen in circulation 
by mediating their effects at the cellular level 
PR (Progesterone receptors) Proteins that bind to progesterone in 
circulation by mediating their effects at the 
cellular level 
Ki67 (Cell proliferation index) Cell proliferation marker found only in cells 
that are in cell division (G1, S, G2, M phase 
of the cell cycle) 
Confirmation by SISH Technique of in situ hybridization by silver 
that allows the quantification of specific 
HER2 signals using a conventional light-
colored microscope 
Diagnostic method  
Grade 
Dimension 
TNM clinical Staging (cT ; cN ; cM) It corresponds to the clinical staging (Size, 
nodule, metastase, respectively) 
TNM Pathological Staging (yT; yN) Corresponds to post-treatment neoadjuvant 
pathological staging (tumor and nodule, 
respectively) 
Number of nodes analyzed  
Number of lymph nodes affected by the 
disease 
Neoadjuvant chemotherapy  
Adjuvant chemotherapy  
PCR (breast) Occurs when the patient does not present 
residual invasive carcinoma, minimal 
residual cellularity, ductal carcinoma in situ, 
or ganglion metastases in breast, armpit or 
both. 
PCR (armpit) 
PCR (breast + armpit) 
Personal history of cardiac pathology  
Left ventricular ejection fraction Volume of blood ejected to each left 
ventricular systole 
 39 
Presence of cardiotoxicity “Damage to the heart”(61) 
 
HER2 Subtype  
 
3. Variables of clinical staging 
Table 7- Number of patients with different variables os clinical staging 
                                       
Treatment 
 
 
   TNM   Variables 
AT 
Concomitant 
A-T 
Sequencial 
 
Number of patients Number of patients 
T 
T0 0 20 
T1 0 1 
T2 3 5 
T3 5 2 
T4 13 4 
Absent 0 20 
N 
N0 4 4 
N+ 17 7 
Absent 0 21 
M 
M0 19 11 
M1 2 0 
Estrogen 
Receptors 
Positive 15 17 
Negative 6 15 
Absent 0 0 
Progesterone 
Receptors 
Positive 11 14 
Negative 10 18 
Absent 0 0 
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4. New York heart association classification 
Table 8- Degree of heart failure according to symptoms. Adapted from the New York Heart Association 
Classification of IC Symptoms 
Class I 
Absence of symptoms (dyspnea) during 
daily activities. The effort limitation is 
similar to that expected for normal 
individuals 
Class II 
Symptoms triggered by everyday 
activities 
Class III 
Symptoms triggered by activities less 
intense than daily ones or small efforts 
Class IV Symptoms at rest 
 
 
 
 
 
